Luo, Qiang
Mo, Jiezhen http://orcid.org/0000-0002-9404-3786
Chen, Hao
Hu, Zetao
Wang, Baihui
Wu, Jiabing
Liang, Ziyu
Xie, Wenhao
Du, Kangxi http://orcid.org/0000-0002-7985-7861
Peng, Maolin
Li, Yingping
Li, Tianyang
Zhang, Yangyi
Shi, Xiaoyan
Shen, Wen-Hui http://orcid.org/0000-0001-7988-6382
Shi, Yang http://orcid.org/0000-0001-9713-1709
Dong, Aiwu http://orcid.org/0000-0002-2075-4235
Wang, Hailin http://orcid.org/0000-0002-1843-999X
Ma, Jinbiao http://orcid.org/0000-0002-0232-1786
Funding for this research was provided by:
National Natural Science Foundation of China (31230041)
Article History
Received: 1 September 2021
Accepted: 12 September 2022
First Online: 26 September 2022
Competing interests
: Y.S. is a co-founder and member of the Scientific Advisory Broad of K36 Therapeutics. Y.S. is also a member of the Scientific Advisory Board of EPICRISPR BIOTECHNOLOGIES, INC, the College of Life Sciences, West Lake University, and a member of the MD Anderson External Advisory Board. Y.S. is a scientific consultant for CBio-X Holdings, Inc., and holds equity in Imago Biosciences, Active Motif, K36 Therapeutics and Epicrispr Biotechnologies, Inc. All other authors declare no competing interests.